Skip to main content
Terug
Watch Compare

Polaryx Therapeutics, Inc.

Datakwaliteit: 83%
PLYX
NASDAQ Manufacturing Chemicals
€ 6,17
▲ € 0,49 (8,63%)
Marktkapitalisatie: 265,27 M
6 months return
—
Momentum
Neutral
ROE
-196,82%

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -3,94 M

Price History

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-196,82%
Onder sectorgemiddelde (-54,44%)
ROIC-135,35%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio8,55
Interest CoverageN/A

Waardering

PE (TTM)
-29,52
Onder sectorgemiddelde (-1,49)
P/B Ratio58,11
EV/EBITDAN/A
Dividend YieldN/A

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -29,5 -1,5
P/B 58,1 1,6
ROE % -196,8 -54,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3

Koersdoel Analisten

1 analist

Consensus van analisten: gemiddeld koersdoel vs huidige prijs en beoordeling.

Strong Buy
Huidig
€ 6,17
+62.1%
Koersdoel
€ 10,00
€ 10,00
€ 10,00
€ 10,00
Vooruitzicht
Forward WPA -€ 0,28
Omzet Sch. 0,0

Winstschattingen

Analistprognoses voor EPS en omzet per periode. Jaar = boekjaren; kwartaal = komende kwartalen.

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,28
-€ 0,28 – -€ 0,28
0,0 1
FY2026 -€ 0,12
-€ 0,12 – -€ 0,12
0,0 1

Winstverassingen

Laatste 1 kwartaal
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,02 -€ 0,16 -700,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -8,99 M
ROE -196,82% ROA -173,79%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -3,94 M
ROIC -135,35% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,55
Interest Coverage N/A Asset Turnover N/A
Working Capital 4,57 M Tangible Book Value 4,57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -29,52 Forward P/E N/A
P/B Ratio 58,11 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1,49%
Market Cap 265,27 M Enterprise Value 260,12 M
Per Share
EPS (Diluted TTM) -0,20 Revenue / Share N/A
FCF / Share -0,09 OCF / Share -0,09
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 43,90%
SBC-Adj. FCF -8,67 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue —
Net Income -8,99 M
EPS (Diluted) -0,20
Gross Profit —
Operating Income -7,82 M
EBITDA —
R&D Expenses 6,27 M
SG&A Expenses —
D&A —
Interest Expense —
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 5,17 M
Total Liabilities 605.000,0
Shareholders' Equity 4,57 M
Total Debt —
Cash & Equivalents 5,14 M
Current Assets 5,17 M
Current Liabilities 605.000,0